reviewJournal of Hematology & OncologyJan 4, 2024GOLD OA

The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

QWQing WeiPLPeijing LiTYTeng YangJZJiayu ZhuLSLu Sun

Chinese Academy of Sciences · Zhejiang Cancer Hospital · +10 more institutions

PubMed
Indexed incrossrefdoajpubmed

Abstract

Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have revolutionized the treatment paradigm of solid tumors. To date, many ongoing studies of ADC combinations with a variety of anticancer drugs, encompassing chemotherapy, molecularly targeted agents, and immunotherapy, are being rigorously conducted in both preclinical studies and clinical trial settings. Nevertheless, combination therapy does not always guarantee a synergistic or additive effect and may entail overlapping toxicity risks. Therefore, understanding the current status and underlying mechanisms of ADC combination therapy is urgently required. This comprehensive review analyzes existing evidence concerning the…

Citation impact

140
total citations
FWCI
35.27
Percentile
100%
References
219
Citations per year

Authors

17

Topics & keywords

Topics
Keywords
  • Medicine
  • Clinical trial
  • Drug
  • Immunotherapy
  • Clinical Practice
  • Combination therapy
  • Antibody therapy
  • Cancer therapy
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding